Cytokinetics

Cytokinetics

Biotechnology
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

$7.8B

Market Cap • 11/10/2026

1997

(29 years)

Founded

2004

(22 years ago)

IPO

NASDAQ

Listing Exchange

Flag of United States

United States

Country

Valuation

P/B

—

P/S

69,1

P/EBITDA

—

P/OCF

—

P/FCF

—

P/E

—

BVPS

—

EPS

—

Market Cap

Market Cap

7,8B

EV

8B

EV/Revenue

70,3

EV/EBITDA

-11,5

EV/EBIT

-11,3

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

-18,5%

Total Yield

-18,5%

Payout

0%

Retained Earnings

-4,1B

Profitability

Gross Margin

90,9%

EBITDA Margin

—

EBIT Margin

—

Net Margin

—

D&A/EBITDA

0%

R&D/Revenue

350,4%

Capex/Revenue

14,7%

Capex/D&A

122,9%

Capex/OCF

-2,9%

SBC/OCF

—

% PPE

8,1%

% Goodwill

0%

ROE

184,7%

ROIC

—

Growth

CAGR Revenue 5Y

39,4%

CAGR Op. Income 5Y

28,6%

CAGR Net Income 5Y

27,7%

CAGR EPS 5Y

14,3%

CAGR OCF 5Y

65,8%

Leverage

N.D./EBITDA

—

Debt/Equity

0%

Current Ratio

3,4

Quick Ratio

3,3

Interest Coverage

—

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium